Bevacizumab in Treating Patients With Recurrent or Progressive Meningiomas

Summary

RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. PURPOSE: This phase II trial is studying how well bevacizumab works in treating patients with recurrent or progression meningiomas.

Timeline

Start

2010-06-17

Primary completion

2014-03-10

Completion

2018-12-31

Drugs

Indications